Medigene AG is a biotechnology company that specializes in the development and commercialization of immunotherapies for the treatment of cancer. The company is committed to improving the lives of patients by focusing on innovative research and development. Medigene AG's corporate philosophy is based on scientific excellence, collaboration, and dedication to achieving meaningful breakthroughs in immune-oncology. By leveraging cutting-edge technologies and a deep understanding of the immune system, Medigene AG strives to develop targeted therapies that provide safe and effective solutions for patients suffering from various types of cancer.

Medigene AG is primarily present in Germany and the United States.

Medigene AG, a well-established biotechnology company, has achieved several significant milestones. Notably, Medigene successfully entered into a collaboration agreement with bluebird bio, a leading gene therapy company, to develop T-cell receptor-modified T cells (TCR-Ts) for cancer immunotherapy. This partnership aims to advance next-generation therapies for solid tumors and hematological malignancies. Additionally, Medigene's proprietary technology platform, TCR Bispecifics, has demonstrated promising results in preclinical studies, showing potential for enhanced tumor targeting and efficacy. The company has also secured various financing agreements, enabling further research and development. Medigene AG remains committed to advancing innovative immunotherapies and improving the lives of patients with cancer.

Medigene AG is a biotechnology company based in Germany. It was founded in 1994 and has since focused on the development of immunotherapy treatments for cancer. Medigene AG has a strong scientific background and expertise in T cell receptor (TCR) technologies. The company's innovative approach involves the identification and use of specific TCRs to stimulate the body's immune system to target cancer cells. Medigene AG has been actively involved in research collaborations and has a diverse pipeline of therapies in development, including personalized TCR therapies. This dedication to advancing immunotherapies makes Medigene AG an important player in the field of cancer treatment.

The main competitors of Medigene AG in the market include companies such as Inovio Pharmaceuticals, Inc., Adaptimmune Therapeutics plc, and Immatics Biotechnologies GmbH.

Medigene AG is primarily active in the biotechnology industry.

Medigene AG is a biotechnology company with a robust and innovative business model. They focus on the development and commercialization of personalized immunotherapies for the treatment of cancer. Medigene utilizes cutting-edge technologies to identify and stimulate the body's immune system to fight against cancer cells, offering promising potential for better patient outcomes. Their extensive expertise in immunotherapy and clinical research enables Medigene AG to advance novel therapeutic approaches, aiming to enhance the quality of life for cancer patients worldwide. With its strategic partnerships and a strong pipeline, Medigene AG is dedicated to revolutionizing cancer treatment through personalized medicine.

Medigene KGV ir -3,18.

Medigene KUV ir 1,92.

AlleAktien kvalitātes vērtējums Medigene ir 3/10.

gaidāmā Medigene apgrozījums ir 11,22 milj. EUR.

gaidāmā Medigene peļņa ir -6,76 milj. EUR.

Medigene AG is a leading biopharmaceutical company based in Martinsried near Munich, specializing in the development of innovative therapeutics for the treatment of cancer and other immune system disorders. The company's business model is based on a wide range of products targeting various therapeutic approaches, supported by a robust platform technology that enables the rapid and targeted development of new treatment options. Medigene's core strategy is focused on the research and development of T-cell-based immunotherapies for cancer treatment, utilizing genetically modified T-cells to target and destroy cancer cells without harming healthy cells and tissues. The company also focuses on the development of antibodies for cancer treatment and utilizes a diverse platform technology to efficiently develop new therapy options. Medigene has a strong pipeline of preclinical and clinical projects in various stages of development, and collaborates extensively with other companies and research institutions to access the latest technologies and research findings. Overall, Medigene is a significant player in the biotechnology industry, with an innovative business and research approach, a broad technological platform, and a strong financial foundation to continue expanding its research and development efforts and enter new markets.

Medigene izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Medigene vai uzņēmums nedod dividendes.

Medigene ISIN ir DE000A1X3W00.

Medigene WKN ir A1X3W0.

Medigene simbols ir MDG1.DE.

Pēdējo 12 mēnešu laikā Medigene maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Medigene plāno maksāt dividendes 0 EUR apmērā.

Medigene pašreizējā dividendu rentabilitāte ir .

Medigene maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Medigene pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 EUR. Tas atbilst dividendes ražībai 0 %.

Medigene tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Medigene apmērā 0 EUR, kas tika izmaksāta 16.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 16.11.2024..

Pēdējās dividendes izmaksa notika 16.11.2024..

Gadā 2023, Medigene izmaksāja 0 EUR dividendes.

Medigene dividendes tiek izmaksātas EUR.